About: Evaluation of Serologic and Antigenic Relationships Between Middle Eastern Respiratory Syndrome Coronavirus and Other Coronaviruses to Develop Vaccine Platforms for the Rapid Response to Emerging Coronaviruses

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of Serologic and Antigenic Relationships Between Middle Eastern Respiratory Syndrome Coronavirus and Other Coronaviruses to Develop Vaccine Platforms for the Rapid Response to Emerging Coronaviruses Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Evaluation of Serologic and Antigenic Relationships Between Middle Eastern Respiratory Syndrome Coronavirus and Other Coronaviruses to Develop Vaccine Platforms for the Rapid Response to Emerging Coronaviruses
Creator	Zambon, Maria Baric, Ralph Gralinski, Lisa Agnihothram, Sudhakar Yount, Boyd Donaldson, Eric Scobey, Trevor Gopal, Robin Menachery, Vineet Denison, Mark Graham, Rachel
source	Medline; PMC; WHO
abstract	Background. Middle East respiratory syndrome coronavirus (MERS-CoV) emerged in 2012, causing severe acute respiratory disease and pneumonia, with 44% mortality among 136 cases to date. Design of vaccines to limit the virus spread or diagnostic tests to track newly emerging strains requires knowledge of antigenic and serologic relationships between MERS-CoV and other CoVs. Methods. Using synthetic genomics and Venezuelan equine encephalitis virus replicons (VRPs) expressing spike and nucleocapsid proteins from MERS-CoV and other human and bat CoVs, we characterize the antigenic responses (using Western blot and enzyme-linked immunosorbent assay) and serologic responses (using neutralization assays) against 2 MERS-CoV isolates in comparison with those of other human and bat CoVs. Results. Serologic and neutralization responses against the spike glycoprotein were primarily strain specific, with a very low level of cross-reactivity within or across subgroups. CoV N proteins within but not across subgroups share cross-reactive epitopes with MERS-CoV isolates. Our findings were validated using a convalescent-phase serum specimen from a patient infected with MERS-CoV (NA 01) and human antiserum against SARS-CoV, human CoV NL63, and human CoV OC43. Conclusions. Vaccine design for emerging CoVs should involve chimeric spike protein containing neutralizing epitopes from multiple virus strains across subgroups to reduce immune pathology, and a diagnostic platform should include a panel of nucleocapsid and spike proteins from phylogenetically distinct CoVs.
has issue date	2013-11-18(xsd:dateTime)
bibo:doi	10.1093/infdis/jit609
bibo:pmid	24253287
has license	bronze-oa
sha1sum (hex)	df0d9d8d2b4b1b8739e29c7fc5cfc4a3c67ce7ea
schema:url	https://doi.org/10.1093/infdis/jit609
resource representing a document's title	Evaluation of Serologic and Antigenic Relationships Between Middle Eastern Respiratory Syndrome Coronavirus and Other Coronaviruses to Develop Vaccine Platforms for the Rapid Response to Emerging Coronaviruses
has PubMed Central identifier	PMC3952667
has PubMed identifier	24253287
schema:publication	The Journal of Infectious Diseases
resource representing a document's body	covid:df0d9d8d2b4b1b8739e29c7fc5cfc4a3c67ce7ea#body_text
is schema:about of	named entity 'RAPID' named entity 'CORONAVIRUS' named entity 'emerged' covid:arg/df0d9d8d2b4b1b8739e29c7fc5cfc4a3c67ce7ea named entity 'EVALUATION' named entity 'RESPONSE TO' named entity 'DESIGN' named entity 'VACCINES' named entity 'SEROLOGIC' named entity 'VIRUS' named entity 'RELATIONSHIPS' named entity 'DATE' named entity 'LIMIT' named entity 'MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS' named entity 'MIDDLE EASTERN RESPIRATORY SYNDROME' named entity 'VACCINE' named entity 'CASES' named entity 'SEROLOGIC' named entity 'RELATIONSHIPS' named entity 'CORONAVIRUSES' named entity 'SPREAD' named entity 'MORTALITY' named entity 'STRAINS' named entity 'TO TRACK' named entity 'CAUSING' named entity 'NEWLY' named entity '136' named entity 'SEVERE' named entity 'PNEUMONIA' named entity 'BACKGROUND' named entity 'KNOWLEDGE' named entity 'ACUTE RESPIRATORY DISEASE' named entity 'DIAGNOSTIC TESTS' named entity 'COVS' named entity 'track' named entity 'respiratory disease' named entity 'respiratory disease' named entity 'serologic' named entity 'Coronaviruses' named entity 'Middle Eastern Respiratory Syndrome Coronavirus' named entity 'Coronaviruses' named entity 'Rapid Response' named entity 'virus' named entity 'HCoV-NL63' named entity 'zoonotic' named entity 'MERS-CoV' named entity 'Venezuelan equine encephalitis virus' named entity 'SARS' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'nucleocapsid' named entity 'serologic' named entity 'cross-reactivity' named entity 'Betacoronavirus' named entity 'reverse-transcription polymerase chain reaction' named entity 'type 1' named entity 'subgenomic mRNA' named entity 'deep sequencing' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'mutation' named entity 'protein' named entity 'antisera' named entity 'kanamycin' named entity 'antisera' named entity 'Calu-3' named entity 'nucleocapsid' named entity 'HKU' named entity 'severe pneumonia' named entity 'Calu-3' named entity 'S protein'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software